ImpactAlpha, April 14 – Don’t refer to conventional finance as ‘mainstream,’ ImpactAlpha’s David Bank said on The Call earlier this month. Call it ‘legacy finance’ in the same way the tech community refers to ‘legacy’ computer systems that are outdated but still in use. That was one takeaway from The Call No. 10, which took ImpactAlpha
An innovative financing mechanism for drugs for neglected diseases is providing a return for impact investors. Novo Nordisk, the Danish pharmaceutical giant, disclosed that it is the buyer of a “priority review voucher” from Medicines Development for Global Health, an Australian nonprofit that won U.S. Food and Drug Administration approval for moxidectin as a treatment
- A contrarian story is emerging in cleantech venture capital.
- Adobe Mezzanine Fund II has backed three ventures so far: renewable energy company HEG, education-focused startups IPETH and (most recently) Kuepa.
- “Small facilities [like this] force you to look for smaller and more difficult companies, to really go deep and look for the small gems which have a huge potential but are not seen as “bankable",” Rabobank’s Arindom Datta told ImpactAlpha.
- Featured: "The better fund managers of color perform, the more racial bias they face"
- A new study of how investors evaluate funds and allocate capital suggests a persistent and systemic explanation for the homogeneity of the investment managers selected by such asset allocators: implicit racial bias.